And it’s not just $1.48 or so. If they hit $250m
Post# of 148181
(Total Views: 682)
Posted On: 06/27/2022 10:36:13 PM
And it’s not just $1.48 or so. If they hit $250mm annual rev sales target over 4 consecutive Q‘s and/or (looks like) US approval of a combo therapy treatment, there is up to another $1 of CVR folks get making the ultimate acquisition price closer to $2.50 or a $410mm mkt cap ballpark. Question is how much of a discount to the ultimate revenue stream that will end up being.
To ohms point - CYDY should demand a higher premium and/or have a competitive bidding process or partnerships once someone bites. And if they get the HIV BLA (and approval) then that should put a decent floor in the negotiations to start from. So plenty of differences here (thanks for mentioning this to both Drano and ohm)
To ohms point - CYDY should demand a higher premium and/or have a competitive bidding process or partnerships once someone bites. And if they get the HIV BLA (and approval) then that should put a decent floor in the negotiations to start from. So plenty of differences here (thanks for mentioning this to both Drano and ohm)
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼